PRME Prime Medicine (PRME) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001894562
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
85
13F, latest reported quarter
Prime Medicine insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Prime Medicine, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 16, 2023.
- The trade is 46.0% of the 3,262,440 shares held after it.
- 3 other insiders bought within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Alphabet Inc. bought about $5.0M of PRME on Aug 1, 2025, the largest insider purchase at the company since 2024; 3 other insiders bought within 30 days and 85 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Feb 15, 2024.
- -1.6% median (-1.6% mean) 90-day return after 2 previous buys.
- The trade is 48.6% of the 6,230,300 shares held after it.
- 3 other insiders bought within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director NELSEN ROBERT bought about $10.0M of PRME on Aug 1, 2025, the largest insider purchase at the company since 2024; 3 other insiders bought within 30 days and 85 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 48.6% of the 6,230,300 shares held after it.
- 3 other insiders bought within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ARCH Venture Fund XII, L.P. bought about $10.0M of PRME on Aug 1, 2025, the largest insider purchase at the company since 2024; 3 other insiders bought within 30 days and 85 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 48.6% of the 6,230,300 shares held after it.
- 3 other insiders bought within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider GILLIS STEVEN bought about $10.0M of PRME on Aug 1, 2025, the largest insider purchase at the company since 2024; 3 other insiders bought within 30 days and 85 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jun 23, 2025.
- +167.3% median (+155.9% mean) 90-day return after 3 previous buys.
- The trade is 0.1% of the 20,240,945 shares held after it.
- No other insider bought within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Liu David R. bought about $52.9K of PRME on Jun 30, 2025; 85 funds added in the latest 13F quarter.51 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
85 funds bought in last quarter
more than 62% of Pharma & Biotech
Revenue
+55.3% year over year
more than 78% of Pharma & Biotech
Margin
-4342.4% net margin
below 96% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
28.6% of the float short (float per yahoo 2026-10-26) · 8.4 days to cover · settled 2026-09-30
more than 91% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PRME
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-32.9%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PRME: institutional holders (13F)
13F holdings, latest reported quarter
16,562,498 sh
$61.1M
9,602,041 sh
$35.4M
8,348,746 sh
$30.8M
7,576,460 sh
$28.0M
4,522,640 sh
$16.7M
Congress trades in PRME
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PRME planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
PRME mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
ARK Genomic Revolution ETF
$21.9M position · as of 2026-07-31
1.4%
Jacob Discovery Fund
$142.0K position · as of 2026-05-31
0.9%
AXS Green Alpha ETF
$497.1K position · as of 2026-06-30
0.9%
Virtus Biotech Clinical Trials Etf
$327.1K position · as of 2026-07-31
0.7%
Global X Genomics & Biotechnology ETF
$188.5K position · as of 2026-05-31
0.3%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$19.3M position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 4 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Not applicable
1 active
3
Multi-phase
3 active
What changed recently
A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson
2026-09-02 · Not Yet Recruiting → Recruiting
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 85 funds added last quarter. Each figure is a federal filing, dated the day it went public.
PRME financials
Revenue growth
+55.3%
XBRL, annual
Net margin
-4342.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.6M
four quarters, 2025-01-01 to 2025-12-31
Revenue, TTM PRME
| FY Dec 2025 | $4.6M |
| FY Dec 2024 | $3.0M |
| FY Dec 2023 | $0 |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $838.0K |
| Sep 2025 | $1.2M |
| Jun 2025 | $1.1M |
| Mar 2025 | $1.5M |
| Dec 2024 | $2.2M |
| Sep 2024 | $209.0K |
At each fiscal year end
Single quarter
Net margin, TTM
-4,056%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PRME
| FY Dec 2025 | -4,342% |
| FY Dec 2024 | -6,567% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -5,499% |
| Sep 2025 | -4,129% |
| Jun 2025 | -4,717% |
| Mar 2025 | -3,569% |
| Dec 2024 | -1,937% |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$156.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PRME
| FY Dec 2025 | -$167.1M |
| FY Dec 2024 | -$130.2M |
| FY Dec 2023 | -$174.1M |
| FY Dec 2022 | -$147.9M |
| FY Dec 2021 | n/a |
| Jun 2026 | -$41.1M |
| Mar 2026 | -$42.9M |
| Dec 2025 | -$37.5M |
| Sep 2025 | -$35.3M |
| Jun 2025 | -$43.0M |
| Mar 2025 | -$51.3M |
| Dec 2024 | $14.5M |
| Sep 2024 | -$27.2M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity PRME
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt PRME
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-373.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PRME
| FY Dec 2025 | -146.8% |
| FY Dec 2024 | -136.9% |
| FY Dec 2023 | -88.2% |
| FY Dec 2022 | -152.2% |
| FY Dec 2021 | n/a |
| Jun 2026 | -373.3% |
| Mar 2026 | -216.1% |
| Dec 2025 | -146.8% |
| Sep 2025 | -112.3% |
| Jun 2025 | -154.8% |
| Mar 2025 | -115.2% |
| Dec 2024 | -136.9% |
| Sep 2024 | -114.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-71.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PRME
| FY Dec 2025 | -62.8% |
| FY Dec 2024 | -79.7% |
| FY Dec 2023 | -71.5% |
| FY Dec 2022 | -36.8% |
| FY Dec 2021 | -54.8% |
| Jun 2026 | -71.2% |
| Mar 2026 | -63.7% |
| Dec 2025 | -62.8% |
| Sep 2025 | -55.0% |
| Jun 2025 | -74.0% |
| Mar 2025 | -63.2% |
| Dec 2024 | -79.7% |
| Sep 2024 | -76.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital PRME
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-85.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PRME
| FY Dec 2025 | -73.8% |
| FY Dec 2024 | -102.0% |
| FY Dec 2023 | -87.0% |
| FY Dec 2022 | -40.4% |
| FY Dec 2021 | n/a |
| Jun 2026 | -85.0% |
| Mar 2026 | -74.8% |
| Dec 2025 | -73.8% |
| Sep 2025 | -63.3% |
| Jun 2025 | -84.4% |
| Mar 2025 | -71.1% |
| Dec 2024 | -102.0% |
| Sep 2024 | -91.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing PRME
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value PRME
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-24.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield PRME
| FY Dec 2025 | -26.7% |
| FY Dec 2024 | -34.0% |
| FY Dec 2023 | -20.2% |
| FY Dec 2022 | -8.2% |
| FY Dec 2021 | n/a |
| Jun 2026 | -23.5% |
| Mar 2026 | -25.3% |
| Dec 2025 | -26.7% |
| Sep 2025 | -15.4% |
| Jun 2025 | -33.0% |
| Mar 2025 | -42.7% |
| Dec 2024 | -34.0% |
| Sep 2024 | -41.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing PRME
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $4.6M | $3.0M | $0 | $0 |
| Operating income | -$208.3M | -$202.5M | -$204.8M | -$116.5M |
| Net income | -$201.1M | -$195.9M | -$198.1M | -$121.8M |
| EPS (diluted) | -1.35 | -1.65 | -2.18 | -4.19 |
| Operating cash flow | -$162.6M | -$122.9M | -$165.4M | -$131.8M |
| Cash | $63.0M | $182.5M | $41.6M | $187.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
PRME Stock Sonar score 4/7 axes
Find similar shapesComparePRME ranks highest on growth (78th percentile) and institutional and government (62nd), and lowest on profitability (25th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
